Casey A Maguire

List of Publications by Year
in descending order

49 papers	4,807 citations	159358 30 h-index	205818 48 g-index
50 all docs	50 docs citations	50 times ranked	7694 citing authors

#	Article	IF	Citations
1	The AAV9 Variant Capsid AAV-F Mediates Widespread Transgene Expression in Nonhuman Primate Spinal Cord After Intrathecal Administration. Human Gene Therapy, 2022, 33, 61-75.	1.4	16
2	Schwannoma Gene Therapy via Adeno-Associated Viral Vector Delivery of Apoptosis-Associated Speck-like Protein Containing CARD (ASC): Preclinical Efficacy and Safety. International Journal of Molecular Sciences, 2022, 23, 819.	1.8	2
3	Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2. Molecular Therapy - Methods and Clinical Development, 2022, , .	1.8	5
4	Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin. Science Advances, 2021, 7, .	4.7	17
5	AAV-S: A versatile capsid variant for transduction of mouse and primate inner ear. Molecular Therapy - Methods and Clinical Development, 2021, 21, 382-398.	1.8	40
6	Delivering AAV to the Central Nervous and Sensory Systems. Trends in Pharmacological Sciences, 2021, 42, 461-474.	4.0	18
7	Neutralizing Antibody Evasion and Transduction with Purified Extracellular Vesicle-Enveloped Adeno-Associated Virus Vectors. Human Gene Therapy, 2021, 32, 1457-1470.	1.4	16
8	Gene therapy for Alzheimerâ€™s disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation. Human Molecular Genetics, 2020, 29, 2920-2935.	1.4	55
9	AAVâ€mediated gene transfer of DNase I in the liver of mice with colorectal cancer reduces liver metastasis and restores local innate and adaptive immune response. Molecular Oncology, 2020, 14, 2920-2935.	2.1	53
10	In vivo engineering of lymphocytes after systemic exosome-associated AAV delivery. Scientific Reports, 2020, 10, 4544.	1.6	20
11	Viral vectors for gene delivery to the inner ear. Hearing Research, 2020, 394, 107927.	0.9	26
12	Preclinical testing of AAV9-PHP.B for transgene expression in the non-human primate cochlea. Hearing Research, 2020, 394, 107930.	0.9	39
13	Selection of an Efficient AAV Vector for Robust CNS Transgene Expression. Molecular Therapy - Methods and Clinical Development, 2019, 15, 320-332.	1.8	89
14	Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1. Molecular Therapy - Methods and Clinical Development, 2019, 15, 18-26.	1.8	17
15	High levels of AAV vector integration into CRISPR-induced DNA breaks. Nature Communications, 2019, 10, 4439.	5.8	257
16	Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo. Neuro-Oncology, 2019, 21, 854-866.	0.6	18
17	Gene Transfer with AAV9-PHP.B Rescues Hearing in a Mouse Model of Usher Syndrome 3A and Transduces Hair Cells in a Non-human Primate. Molecular Therapy - Methods and Clinical Development, 2019, 13, 1-13.	1.8	110
18	Intrathecal Adeno-Associated Viral Vector-Mediated Gene Delivery for Adrenomyeloneuropathy. Human Gene Therapy, 2019, 30, 544-555.	1.4	21

#	Article	IF	Citations
19	CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimerâ€™s Disease. Molecular Therapy - Nucleic Acids, 2018, 11, 429-440.	2.3	116
20	Extracellular vesicles: nature's nanoparticles for improving gene transfer with adenoâ€associated virus vectors. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2018, 10, e1488.	3.3	29
21	Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery. Journal of Neuro-Oncology, 2018, 139, 293-305.	1.4	24
22	Efficient Gene Transfer to the Central Nervous System by Single-Stranded Anc80L65. Molecular Therapy - Methods and Clinical Development, 2018, 10, 197-209.	1.8	62
23	Viral vectors for therapy of neurologic diseases. Neuropharmacology, 2017, 120, 63-80.	2.0	130
24	Rescue of Hearing by Gene Delivery to Inner-Ear Hair Cells Using Exosome-Associated AAV. Molecular Therapy, 2017, 25, 379-391.	3.7	181
25	Exosome-associated AAV2 vector mediates robust gene delivery into the murine retina upon intravitreal injection. Scientific Reports, 2017, 7, 45329.	1.6	108
26	Trafficking of adenoâ€associated virus vectors across a model of the bloodâ€“brain barrier; a comparative study of transcytosis and transduction using primary human brain endothelial cells. Journal of Neurochemistry, 2017, 140, 216-230.	2.1	97
27	Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors. Blood Advances, 2017, 1, 2019-2031.	2.5	90
28	Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16081.	1.8	46
29	In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy. Molecular Therapy, 2016, 24, 1247-1257.	3.7	98
30	Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model. Molecular Therapy - Oncolytics, 2016, 3, 16017.	2.0	21
31	Intracranial AAVâ€sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model ofÂinvasive glioblastoma. Molecular Oncology, 2016, 10, 625-634.	2.1	18
32	Extracellular vesicles and intercellular communication within the nervous system. Journal of Clinical Investigation, 2016, 126, 1198-1207.	3.9	188
33	Applying extracellular vesicles based therapeutics in clinical trials â€“ an ISEV position paper. Journal of Extracellular Vesicles, 2015, 4, 30087.	5.5	1,020
34	Heparin affinity purification of extracellular vesicles. Scientific Reports, 2015, 5, 10266.	1.6	152
35	Adenoassociated Virus Serotype 9-Mediated Gene Therapy for X-Linked Adrenoleukodystrophy. Molecular Therapy, 2015, 23, 824-834.	3.7	51
36	Bioluminescence-Based Monitoring of Virus Vector-Mediated Gene Transfer in Mice. Methods in Molecular Biology, 2014, 1098, 197-209.	0.4	0

#	Article	IF	Citations
37	Gene Therapy for the Nervous System: Challenges and New Strategies. Neurotherapeutics, 2014, 11, 817-839.	2.1	70
38	Extracellular Vesicles as Enhancers of Virus Vectorâ€"Mediated Gene Delivery. Human Gene Therapy, 2014, 25, 785-786.	1.4	13
39	Dynamic Biodistribution of Extracellular Vesicles <i>in Vivo</i> Using a Multimodal Imaging Reporter. ACS Nano, 2014, 8, 483-494.	7.3	663
40	Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery inÂvivo. Biomaterials, 2014, 35, 7598-7609.	5.7	112
41	Mouse Gender Influences Brain Transduction by Intravascularly Administered AAV9. Molecular Therapy, 2013, 21, 1470-1471.	3.7	33
42	Heparin blocks transfer of extracellular vesicles between donor and recipient cells. Journal of Neuro-Oncology, 2013, 115, 343-351.	1.4	156
43	Triple Bioluminescence Imaging for In Vivo Monitoring of Cellular Processes. Molecular Therapy - Nucleic Acids, 2013, 2, e99.	2.3	77
44	Microvesicle-associated AAV Vector as a Novel Gene Delivery System. Molecular Therapy, 2012, 20, 960-971.	3.7	236
45	Codon-optimized Luciola italica luciferase variants for mammalian gene expression in culture and in vivo. Molecular Imaging, 2012, 11, 13-21.	0.7	6
46	Directed evolution of adeno-associated virus for glioma cell transduction. Journal of Neuro-Oncology, 2010, 96, 337-347.	1.4	43
47	<i>Gaussia</i> Luciferase Variant for High-Throughput Functional Screening Applications. Analytical Chemistry, 2009, 81, 7102-7106.	3.2	74
48	Preventing Growth of Brain Tumors by Creating a Zone of Resistance. Molecular Therapy, 2008, 16, 1695-1702.	3.7	39
49	Valproic acid enhances gene expression from viral gene transfer vectors. Journal of Virological Methods, 2005, 125, 23-33.	1.0	35